Verici Dx is using its latest Coffee and Cases session to directly connect its transplant diagnostics offering with real-world patient outcomes, highlighting factors that influence clinical adoption beyond technical performance.
The event, scheduled for 26 March 2026 at 12pm CST, features Tiffany Archibald, a patient advocate and rare disease specialist who has undergone three kidney transplants. Her experience provides a practical lens on the challenges faced across the transplant journey, including diagnosis, monitoring, and long-term care.
Adoption in transplant diagnostics depends on how effectively tools fit into clinical workflows and patient management. By focusing on lived experience, Verici Dx is reinforcing the role its technology can play in addressing gaps in care, particularly in complex or underdiagnosed conditions.
Verici Dx Plc (LON:VRCI) is developing a complementary suite of proprietary, leading-edge tests forming a kidney transplant diagnostics platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes.
